Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs Propofol for ERCP Sedation
NCT04658173Unknown
- Sponsor
- Tianjin Nankai Hospital
- Start
- Dec 2020
- Primary completion
- Oct 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of remimazolam in Procedural sedation (PS) (2 arms), sponsored by Tianjin Nankai Hospital. Primary endpoint: The occurrence of hypoxia at 1 day. Status: unknown.
02
Drugs
remimazolam
03
Conditions
Procedural sedation (PS)
Beyond the preview
Go deeper on NCT04658173.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04658173.